[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, Hyun SH, Park K, Ahn MJ, Ahn YC, Kim HJ, Ko YH, Baek CH: Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res; 2009 Sep 15;15(18):5861-8
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer.
  • PURPOSE: This study aimed to investigate whether metabolic tumor volume (MTV) measured from [(18)F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) predicts short-term outcome to radiotherapy with or without chemotherapy and disease-free survival (DFS) in patients with pharyngeal cancers.
  • Short-term outcome was assessed using the treatment response evaluation by the Response Evaluation Criteria in Solid Tumors and recurrence events during follow-up (complete response/no recurrence or residual disease/recurrence).
  • A cutoff of 40 mL for the MTV was the best discriminative value for predicting treatment response.
  • By univariate analyses, patients with MTV > 40 mL showed a significantly lower number of complete response/no recurrence than did patients with MTV < or =40 mL [68.2% versus 87.8%; hazard ratio (HR), 3.34; 95% confidence interval (95% CI), 1.09-10.08; P = 0.03], as is the same in tumor-node-metastasis stage (87.5% for I-II versus 90% for III versus 63.8% for IV; P = 0.02).
  • The standardized uptake value for the primary tumor did not show any correlation with treatment outcome or DFS.
  • CONCLUSION: MTV has a potential value in predicting short-term outcome and DFS in patients with pharyngeal cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorodeoxyglucose F18. Pharyngeal Neoplasms / diagnosis. Pharyngeal Neoplasms / therapy. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Treatment Outcome. Tumor Burden. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2010 Mar 15;16(6):1968; author reply 1968-9 [20215538.001]
  • (PMID = 19737951.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


2. Rothschild S, Studer G, Seifert B, Huguenin P, Glanzmann C, Davis JB, Lütolf UM, Hany TF, Ciernik IF: PET/CT staging followed by Intensity-Modulated Radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair comparison. Radiat Oncol; 2007 Jun 09;2:22
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET/CT staging followed by Intensity-Modulated Radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair comparison.
  • BACKGROUND: Impact of non-pharmacological innovations on cancer cure rates is difficult to assess.
  • It remains unclear, whether outcome improves with 2- [18-F]-fluoro-2-deoxyglucose-positron emission tomography and integrated computer tomography (PET/CT) and intensity-modulated radiotherapy (IMRT) for curative treatment of advanced pharyngeal carcinoma.
  • PATIENTS AND METHODS: Forty five patients with stage IVA oro- or hypopharyngeal carcinoma were staged with an integrated PET/CT and treated with definitive chemoradiation with IMRT from 2002 until 2005.
  • To estimate the impact of PET/CT with IMRT on outcome, a case-control analysis on all patients with PET/CT and IMRT was done after matching with eighty six patients treated between 1991 and 2001 without PET/CT and 3D-conformal radiotherapy with respect to gender, age, stage, grade, and tumor location with a ratio of 1:2.
  • RESULTS: PET/CT and treatment with IMRT improved cure rates compared to patients without PET/CT and IMRT.
  • CONCLUSION: PET/CT in combination with IMRT and chemotherapy for pharyngeal carcinoma improve oncological therapy of pharyngeal carcinomas.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / radiotherapy. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / radiotherapy. Positron-Emission Tomography / methods. Radiotherapy, Intensity-Modulated / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Conformal / methods. Reproducibility of Results. Treatment Outcome

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1117-26 [10725621.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1309-17 [17289292.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):907-16 [11240231.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):880-914 [11704310.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):1051-7 [12095574.001]
  • [Cites] J Nucl Med. 2003 Jan;44(1):24-9 [12515872.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):312-21 [12527043.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • [Cites] World J Surg. 2003 Jul;27(7):832-7 [14509515.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):853-63 [14529793.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1797-803 [14602862.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):43-50 [15093897.001]
  • [Cites] Am J Surg. 1974 Oct;128(4):562-7 [4421032.001]
  • [Cites] Otolaryngol Head Neck Surg. 1989 Oct;101(4):422-5 [2508017.001]
  • [Cites] Head Neck. 1990 Mar-Apr;12(2):109-13 [2312275.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Nov;116(11):1297-301 [2242260.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1992 Dec;17(6):558-62 [1493637.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Jul;30B(4):225-9 [7950835.001]
  • [Cites] Laryngoscope. 1995 Apr;105(4 Pt 1):373-5 [7715380.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):628-32 [8988664.001]
  • [Cites] Strahlenther Onkol. 1998 Aug;174(8):397-402 [9739379.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4665-73 [15534360.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Head Neck. 2005 Jun;27(6):494-502 [15772951.001]
  • [Cites] Head Neck. 2005 Jun;27(6):478-87 [15772953.001]
  • [Cites] Laryngoscope. 2005 Jul;115(7):1186-90 [15995504.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Oct;2(10):526-33 [16205772.001]
  • [Cites] Clin Radiol. 2005 Nov;60(11):1143-55 [16223611.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73 [15925451.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):143-51 [16618577.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):291-7 [16499982.001]
  • [Cites] Eur J Radiol. 2006 Jun;58(3):383-9 [16476533.001]
  • [Cites] Radiat Oncol. 2006;1:7 [16722599.001]
  • [Cites] Radiother Oncol. 2006 Jun;79(3):249-58 [16564588.001]
  • [Cites] Radiat Oncol. 2006;1:40 [17052346.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):438-44 [17141972.001]
  • [Cites] Head Neck. 2007 Mar;29(3):211-20 [17111429.001]
  • [Cites] Head Neck. 2007 Apr;29(4):387-400 [16358297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • (PMID = 17559684.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1924526
  • [General-notes] NLM/ Original DateCompleted: 20070806
  •  go-up   go-down


3. Montero EH, Trufero JM, Romeo JA, Terré FC: Comorbidity and prognosis in advanced hypopharyngeal-laryngeal cancer under combined therapy. Tumori; 2008 Jan-Feb;94(1):24-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidity and prognosis in advanced hypopharyngeal-laryngeal cancer under combined therapy.
  • AIMS AND BACKGROUND: The success of combined treatment in head and neck cancer resides largely in its completion, which can be compromised when the patient's general health status is precarious.
  • The objective of this investigation was to study the role of comorbidity as a prognostic factor in a large, homogeneous population affected by locally advanced pharyngeal-laryngeal cancer, under a combined protocol treatment.
  • The a priori hypothesis is that comorbidity strongly conditions overall survival and specific overall survival in these patients and can aid in the selection and individualization of treatments.
  • Of the original 114 patients selected, 15 were withdrawn because the tumor spread to maxillofacial areas, or due to the lack of attendance at the clinic, incomplete clinical data or coexistent primary tumors.
  • The group under analysis consisted of the 99 remaining patients affected by stage III and IV laryngeal and/or hypopharyngeal cancers that had not received previous treatments.
  • In the multivariate analysis, tumor staging, neoadjuvant chemotherapy response and comorbidity (RR = 1.55 and 1.44 for overall and specific overall survival, respectively) present themselves as three prognostic factors independent of overall and specific overall survival.
  • CONCLUSIONS: The role of comorbidity as an independent prognostic factor in patients affected by laryngeal and/or hypopharyngeal cancer treated with chemo-radiotherapy should be taken into account in the tailoring of treatments and the improvement of therapeutic results.
  • [MeSH-minor] Combined Modality Therapy. Comorbidity. Follow-Up Studies. Humans. Middle Aged. Prognosis. Retrospective Studies. Spain / epidemiology. Survival Rate

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18468331.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A: Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol; 2010 Jun 1;28(16):2732-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.
  • PURPOSE: To assess clinical and functional results of chemoradiotherapy for oropharyngeal cancer (OPC), utilizing intensity-modulated radiotherapy (IMRT) to spare the important swallowing structures to reduce post-therapy dysphagia.
  • PATIENTS AND METHODS: This was a prospective study of weekly chemotherapy (carboplatin dosed at one times the area under the curve [AUC, AUC 1] and paclitaxel 30 mg/m(2)) concurrent with IMRT aiming to spare noninvolved parts of the swallowing structures: pharyngeal constrictors, glottic and supraglottic larynx, and esophagus as well as the oral cavity and major salivary glands.
  • Swallowing was assessed by patient-reported Swallowing and Eating Domain scores, observer-rated scores, and videofluoroscopy (VF) before therapy and periodically after therapy through 2 years.
  • All measures of dysphagia worsened soon after therapy; observer-rated and patient-reported scores recovered over time, but VF scores did not.
  • At 1 year after therapy, observer-rated dysphagia was absent or minimal (scores 0 to 1) in all patients except four: one who was feeding-tube dependent and three who required soft diet.
  • From pretherapy to 12 months post-therapy, the Swallowing and Eating Domain scores worsened on average (+/- standard deviation) by 10 +/- 21 and 13 +/- 19, respectively (on scales of 0 to 100), and VF scores (on scale of 1 to 7) worsened from 2.9 +/- 1.5 (mild dysphagia) to 4.1 +/- 0.9 (mild/moderate dysphagia).
  • CONCLUSION: Chemoradiotherapy with IMRT aiming to reduce dysphagia can be performed safely for OPC and has high locoregional tumor control rates.

  • Genetic Alliance. consumer health - Dysphagia.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8 [12007937.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):377-85 [18164838.001]
  • [Cites] Dysphagia. 2003 Winter;18(1):53-7 [12497197.001]
  • [Cites] Med Care. 2003 May;41(5):582-92 [12719681.001]
  • [Cites] Head Neck. 2003 Jun;25(6):432-7 [12784234.001]
  • [Cites] Head Neck. 2004 Apr;26(4):365-72 [15054740.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):28-42 [15093896.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):43-50 [15093897.001]
  • [Cites] Biometrics. 1982 Dec;38(4):963-74 [7168798.001]
  • [Cites] Head Neck. 1993 Nov-Dec;15(6):485-96 [8253555.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Oct;123(10):1125-32 [9339991.001]
  • [Cites] Head Neck. 1998 Jan;20(1):31-7 [9464950.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):615-9 [16027285.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3770-6 [18669465.001]
  • [Cites] Laryngoscope. 2008 Aug;118(8):1357-61 [18528311.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):617-22 [18793966.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1110-8 [18468812.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):737-46 [18486356.001]
  • [Cites] Semin Radiat Oncol. 2009 Jan;19(1):35-42 [19028344.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2008 Dec;117(12):919-24 [19140539.001]
  • [Cites] Radiother Oncol. 2009 Feb;90(2):189-95 [19167120.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1187-95 [19251090.001]
  • [Cites] Br J Radiol. 2009 Aug;82(980):675-80 [19332514.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):385-92 [19553033.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):462-7 [19577862.001]
  • [Cites] Head Neck. 2006 Jan;28(1):64-73 [16302193.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73 [15925451.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Mar;134(3):455-9 [16500444.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):298-305 [16524633.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Jun;134(6):916-22 [16730530.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2606-11 [16763272.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2636-43 [16763277.001]
  • [Cites] Support Care Cancer. 2006 Oct;14(10):988-98 [16794811.001]
  • [Cites] Radiother Oncol. 2006 Sep;80(3):302-6 [16890314.001]
  • [Cites] Am J Clin Oncol. 2006 Dec;29(6):606-12 [17148999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):750-7 [17418971.001]
  • [Cites] Anticancer Res. 2007 May-Jun;27(3B):1663-8 [17595793.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1289-98 [17560051.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):74-82 [17673322.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):64-73 [17714815.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2007 Nov;116(11):837-41 [18074669.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1289-95 [18086974.001]
  • [Cites] Head Neck. 2008 Feb;30(2):148-58 [17786992.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3964-71 [12351593.001]
  • (PMID = 20421546.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA059827; United States / NCI NIH HHS / CA / P50 CA097248; United States / NCI NIH HHS / CA / P01 CA59827; United States / NCI NIH HHS / CA / P50 CA97248
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2881852
  •  go-up   go-down


5. Barasch A, Epstein JB, Foong WC, Clayman L: Intralesional chemotherapy for head and neck carcinoma: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Mar;97(3):307-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional chemotherapy for head and neck carcinoma: a review of the literature.
  • In the last decade chemotherapy has gained widespread acceptance in the treatment of oral and pharyngeal cancer.
  • Current standard treatment for advanced lesions consists of concomitant radiation and chemotherapy.
  • Recent studies have explored the idea that locally delivered cytotoxic drugs could further improve prognosis in this patient population.
  • We review this literature with the objective of popularizing these data and suggesting future directions for treatment and clinical research for head and neck cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Humans. Infusions, Intra-Arterial. Injections, Intralesional. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15024351.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


6. Cojocariu OM, Huguet F, Lefevre M, Périé S: [Prognosis and predictive factors in head-and-neck cancers]. Bull Cancer; 2009 Apr;96(4):369-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Facteurs pronostiques et prédictifs des cancers des voies aérodigestives supérieures.
  • The head-and-neck squamous-cell carcinomas (HNSCC) represent in order of frequency the fourth leading cause of cancer deaths among men in France.
  • For this reason, it is necessary to identify prognostic and predictive factors able to help in the choice of the treatment.
  • The clinical factors with a prognostic value are the tumor location, the tumor size and the lymph node status.
  • More recently, the identification of molecular factors has opened the way to new therapies.
  • 18-alpha-FDG positron emission tomography emerges as a useful tool for the therapeutic evaluation.
  • The evolution of surgical techniques, the development of induction chemotherapy regimen or concurrent ones with radiotherapy and new techniques of conformal irradiation also results in a better locoregional control.
  • [MeSH-minor] Anemia / etiology. Cell Hypoxia. Genes, p53 / genetics. Head and Neck Neoplasms / metabolism. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Head and Neck Neoplasms / virology. Humans. Laryngeal Neoplasms / metabolism. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Laryngeal Neoplasms / virology. Lymphatic Metastasis. Nasopharyngeal Neoplasms / metabolism. Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / therapy. Nasopharyngeal Neoplasms / virology. Neoplasm Proteins / antagonists & inhibitors. Neoplasm Proteins / metabolism. Neoplasm Staging. Papillomavirus Infections / complications. Papillomavirus Infections / virology. Paranasal Sinuses. Pharyngeal Neoplasms / metabolism. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / therapy. Pharyngeal Neoplasms / virology. Prognosis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism. Tumor Burden


7. Wang ZY, Li YX, Wang WH, Jin J, Wang H, Song YW, Liu QF, Wang SL, Liu YP, Qi SN, Fang H, Liu XF, Yu ZH: Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood; 2009 Nov 26;114(23):4771-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents.
  • Extranodal nasal-type natural killer (NK)/T-cell lymphoma is rarely observed in children and adolescents.
  • We aim to investigate the clinical features, prognosis, and treatment outcomes in these patients.
  • Among the patients with stage I and II disease, 19 patients received initial radiotherapy with or without chemotherapy, and 14 patients received chemotherapy followed by radiotherapy.
  • The 4 patients with stage III and IV disease received primary chemotherapy and radiation of the primary tumor.
  • Children and adolescents with extranodal nasal-type NK/T-cell lymphoma usually presented with early-stage disease, high frequency of B symptoms, good performance, low-risk age-adjusted international prognostic index, and chemoresistance.
  • The complete response rate after initial radiotherapy was 73.7%, which was significantly higher than the response rate after initial chemotherapy (16.7%; P = .002).
  • Children and adolescents with early-stage extranodal nasal-type NK/T-cell lymphoma treated with primary radiotherapy had a favorable prognosis.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / radiotherapy. Nose Neoplasms / radiotherapy. Pharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. China. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Kaplan-Meier Estimate. Male. Neoplasm Staging. Prednisone / administration & dosage. Radiotherapy, Intensity-Modulated. Remission Induction. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19812381.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Schwartz DL, Hutcheson K, Barringer D, Tucker SL, Kies M, Holsinger FC, Ang KK, Morrison WH, Rosenthal DI, Garden AS, Dong L, Lewin JS: Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Dec 1;78(5):1356-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To investigate long-term swallowing function in oropharyngeal cancer patients treated with intensity-modulated radiotherapy (IMRT), and to identify novel dose-limiting criteria predictive for dysphagia.
  • METHODS AND MATERIALS: Thirty-one patients with Stage IV oropharyngeal squamous carcinoma enrolled on a Phase II trial were prospectively evaluated by modified barium swallow studies at baseline, and 6, 12, and 24 months post-IMRT treatment.
  • Candidate dysphagia-associated organs at risk were retrospectively contoured into original treatment plans.
  • Thirteen patients (42%) received concurrent chemotherapy during IMRT.
  • Mean dose to glottic larynx for the cohort was limited to 18 Gy (range, 6-39 Gy) by matching IMRT to conventional low-neck fields.
  • RESULTS: Dose-volume constraints (V30 < 65% and V35 < 35% for anterior oral cavity and V55 < 80% and V65 < 30% for high superior pharyngeal constrictors) predictive for objective swallowing dysfunction were identified by univariate and multivariate analyses.
  • CONCLUSIONS: In the context of glottic laryngeal shielding, we describe candidate oral cavity and superior pharyngeal constrictor organs at risk and dose-volume constraints associated with preserved long-term swallowing function; these constraints are currently undergoing prospective validation.

  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704 [11395238.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):870-6 [11448365.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8 [12007937.001]
  • [Cites] Head Neck. 2002 Jun;24(6):555-65 [12112553.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1174-84 [12128118.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1219-30 [14630255.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):615-9 [16027285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1000-5 [15978743.001]
  • [Cites] Radiother Oncol. 2006 Sep;80(3):302-6 [16890314.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1289-98 [17560051.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1813-20 [17546592.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):64-73 [17714815.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1289-95 [18086974.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Lancet. 2008 May 17;371(9625):1695-709 [18486742.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3770-6 [18669465.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):568-74 [18793959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1110-8 [18468812.001]
  • [Cites] Head Neck. 2009 May;31(5):611-7 [19107949.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2294-301 [8635098.001]
  • [Cites] Head Neck. 2003 Dec;25(12):1034-41 [14648862.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1072-82 [15001247.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Sep;130(9):1100-3 [15381598.001]
  • [Cites] J Speech Hear Res. 1994 Apr;37(2):314-25 [8028312.001]
  • [Cites] Dysphagia. 1996 Spring;11(2):93-8 [8721066.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):721-30 [8948358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):83-92 [9588921.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • (PMID = 20646872.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R21 CA132281; United States / NCI NIH HHS / CA / CA132281
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS575664; NLM/ PMC4034521
  •  go-up   go-down


9. Kenady DE, Arnold SM, Regine WF, Mentzer RM Jr: Oral/pharyngeal squamous carcinoma: treatment strategies. J Ky Med Assoc; 2002 Nov;100(11):488-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral/pharyngeal squamous carcinoma: treatment strategies.
  • Oral/pharyngeal squamous carcinoma is a largely preventable problem.
  • Treatment reflects the locally and regionally aggressive nature of these tumors.
  • In advanced disease neither surgery nor radiation therapy can be used as a primary modality, and often combined treatment is necessary.
  • Chemotherapy has a less well-defined role, but is increasing control rates in advanced tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Pharyngeal Neoplasms / therapy
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Kentucky. Laryngectomy / methods. Male. Neoplasm Staging. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / therapy. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12455455.001).
  • [ISSN] 0023-0294
  • [Journal-full-title] The Journal of the Kentucky Medical Association
  • [ISO-abbreviation] J Ky Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


10. Salama JK, Stenson KM, List MA, Mell LK, Maccracken E, Cohen EE, Blair E, Vokes EE, Haraf DJ: Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg; 2008 Oct;134(10):1060-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.
  • OBJECTIVE: To define factors that acutely influenced swallowing function prior to and during concurrent chemotherapy and radiotherapy.
  • DESIGN: A summary score from 1 to 7 (the swallowing performance status scale [SPS]) of oral and pharyngeal impairment, aspiration, and diet, was assigned to each patient study by a single senior speech and swallow pathologist, with higher scores indicating worse swallowing.
  • Generalized linear regression models were formulated to asses the effects of patient factors (performance status, smoking intensity, amount of alcohol ingestion, and age), tumor factors (primary site, T stage, and N stage), and treatment-related factors (radiation dose, use of intensity-modulated radiation therapy, response to induction chemotherapy, postchemoradiotherapy neck dissection, and preprotocol surgery) on the differences between SPS score before and after treatment.
  • PATIENTS: The study included 95 patients treated under a multiple institution, phase 2 protocol who underwent a videofluorographic oropharyngeal motility (OPM) study to assess swallowing function prior to and within 1 to 2 months after the completion of concurrent chemotherapy and radiotherapy.
  • Only T stage (T3 or T4) was associated with improved swallowing after treatment (OR, 8.96; 95% CI, 1.9-41.5; P < .001).
  • CONCLUSION: In patients undergoing concurrent chemotherapy and radiotherapy, improved swallowing function over baseline is associated with advanced T stage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Deglutition Disorders / etiology. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Radiotherapy, High-Energy / adverse effects
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Confidence Intervals. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neck Dissection / adverse effects. Neck Dissection / methods. Neoplasm Staging. Odds Ratio. Probability. Quality of Life. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936351.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Nguyen NP, Smith HJ, Moltz CC, Frank C, Millar C, Dutta S, Lee H, North D, Karlsson U, Vos P, Nguyen LM, Sallah S: Prevalence of pharyngeal and esophageal stenosis following radiation for head and neck cancer. J Otolaryngol Head Neck Surg; 2008 Apr;37(2):219-24
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of pharyngeal and esophageal stenosis following radiation for head and neck cancer.
  • OBJECTIVE: To evaluate the risk and outcome of pharyngoesophageal stenosis in patients who complained of dysphagia following radiation for head and neck cancer.
  • PATIENTS: Patients who complained of persistent dysphagia following radiation alone or combined with surgery or chemotherapy for head and neck cancer.
  • Patients were selected if they were cancer free at the time of the swallowing study.
  • Traditional barium swallow confirmed the diagnosis of pharyngeal (n = 2) or esophageal (n = 14) stenosis in 16 patients.
  • CONCLUSION: Pharyngeal and/or cervical esophageal stenosis may be the cause of dysphagia following radiation for head and neck cancer.
  • [MeSH-major] Esophageal Stenosis / epidemiology. Esophagus / radiation effects. Otorhinolaryngologic Neoplasms / radiotherapy. Pharyngeal Diseases / epidemiology. Pharynx / radiation effects. Radiation Injuries / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Barium Sulfate. Combined Modality Therapy. Constriction, Pathologic / epidemiology. Constriction, Pathologic / radiography. Constriction, Pathologic / therapy. Contrast Media. Cross-Sectional Studies. Deglutition Disorders / epidemiology. Deglutition Disorders / radiography. Dilatation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. United States

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Throat Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19128616.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Contrast Media; 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


12. Lecanu JB, Monceaux G, Périé S, Angelard B, St Guily JL: Conservative surgery in T3-T4 pharyngolaryngeal squamous cell carcinoma: an alternative to radiation therapy and to total laryngectomy for good responders to induction chemotherapy. Laryngoscope; 2000 Mar;110(3 Pt 1):412-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative surgery in T3-T4 pharyngolaryngeal squamous cell carcinoma: an alternative to radiation therapy and to total laryngectomy for good responders to induction chemotherapy.
  • OBJECTIVE: To evaluate the possibility of preservation of the larynx after neoadjuvant chemotherapy by performing a conservative surgery instead of total laryngectomy initially planned, in patients with previously untreated laryngeal and piriform sinus squamous cell carcinoma (SCC).
  • METHODS: A total of 115 patients treated at Tenon Hospital with induction chemotherapy from 1985 to 1995, all with initial indication of radical surgery, were available for the study.
  • The clinical tumor response was evaluated after three cycles of chemotherapy.
  • According to this response, to preserve laryngeal functions, some patients had a modification of the treatment initially planned: radiation therapy essentially for complete responders, and conservative surgery for some partial responders.
  • RESULTS: Of 69 patients with laryngeal cancer, 14 were treated by partial laryngectomy and 19 by radiation therapy; of 46 patients with piriform sinus cancer, 8 were treated by partial surgery and 12 by radiation therapy; the other patients were treated as was initially planned (total laryngectomy with partial pharyngectomy).
  • Overall survival rates, estimated by the Kaplan-Meier method, were not statistically different between the three treatment groups.
  • CONCLUSION: This report is a retrospective study, but these results suggest the possibility of using conservative surgery, instead of initially planned total laryngectomy, for good responders to induction chemotherapy with a small residual tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / surgery. Laryngectomy. Neoadjuvant Therapy. Pharyngeal Neoplasms / surgery
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Linear Models. Lymph Node Excision. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Patient Care Planning. Pharyngectomy. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10718429.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Maguire PD, Meyerson MB, Neal CR, Hamann MS, Bost AL, Anagnost JW, Ungaro PC, Pollock HD, McMurray JE, Wilson EP, Kotwall CA: Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community. Int J Radiat Oncol Biol Phys; 2004 Mar 1;58(3):698-704
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
  • PURPOSE: To evaluate efficacy and toxicity of the Duke University chemoirradiation regimen for locally advanced head-and-neck cancer in a regional community cancer center.
  • METHODS AND MATERIALS: Between June 1998 and June 2002, 50 patients with Stage III or IVA squamous cell carcinoma of the head and neck were treated definitively with concurrent combined modality therapy (CMT).
  • Patients received accelerated, hyperfractionated radiotherapy (AFRT), 1.2-1.25 Gy b.i.d., to a median prescribed dose of 70 Gy.
  • Chemotherapy consisted of cisplatin 12 mg and fluorouracil 600 mg/m(2) daily for 5 consecutive days during Weeks 1 and 6, followed by two cycles after AFRT.
  • Patients with N2-N3 neck disease (n = 21; 42%) were considered for neck dissection depending on their response to AFRT and chemotherapy.
  • Twenty-nine patients with Stage III and IVA disease treated between 1991 and 1997 with definitive RT alone served as historical controls.
  • RESULTS: Forty-nine patients (98%) in the CMT group completed the prescribed AFRT and 38 (76%) completed four cycles of chemotherapy.
  • Acute Radiation Therapy Oncology Group Grade 3 toxicities for the CMT group were mucosal (n = 50; 100%), skin (n = 9; 18%), and hematologic (n = 3; 6%).
  • Late Grade 3-4 toxicities consisted of pharyngeal stricture (n = 7; 14%), laryngeal chondritis (n = 3; 6%), osteoradionecrosis (n = 2; 4%), and peripheral neuropathy (n = 1; 2%).
  • CONCLUSION: This aggressive regimen of AFRT with concurrent cisplatin and fluorouracil with or without neck dissection is feasible in the community setting for patients with Stage III and IVA head-and-neck cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14967423.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Rades D, Stoehr M, Meyners T, Bohlen G, Nadrowitz R, Dunst J, Schild SE, Wroblewski J, Albers D, Schmidt R, Alberti W, Tribius S: Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer. Strahlenther Onkol; 2008 Apr;184(4):198-205
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer.
  • BACKGROUND AND PURPOSE: Conventional radiotherapy (RT) still is the standard technique for head-and-neck cancer in many centers worldwide, whereas other centers replaced this technique by 3-D conformal RT, which is associated with more appropriate dose distributions.
  • This study compared both techniques for overall survival (OS), metastases-free survival (MFS), loco-regional control (LC), and toxicity in stage III/IV head-and-neck cancer.
  • PATIENTS AND METHODS: Data of 345 patients irradiated for stage III/IV squamous cell head-and-neck cancer were retrospectively analyzed.
  • Eleven further potential prognostic factors were investigated: age, gender, performance status, tumor site, grading, T-stage, N-stage, AJCC-stage, chemotherapy, surgery, pre-RT hemoglobin.
  • CONCLUSION: Both RT techniques resulted in similar treatment outcomes.
  • Outcome was associated with gender, performance status, tumor stage, and pre-RT hemoglobin.
  • [MeSH-minor] Aged. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / radiotherapy. Pharyngeal Neoplasms / surgery. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398584.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Pauloski BR, Rademaker AW, Logemann JA, Lazarus CL, Newman L, Hamner A, MacCracken E, Gaziano J, Stachowiak L: Swallow function and perception of dysphagia in patients with head and neck cancer. Head Neck; 2002 Jun;24(6):555-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Swallow function and perception of dysphagia in patients with head and neck cancer.
  • BACKGROUND: The relationship between subjective complaints of dysphagia and objective measures of swallow function in patients with cancers of the oral cavity, pharynx, or larynx, treated with radiotherapy +/- chemotherapy has not been well documented in the literature.
  • RESULTS: Patients with complaints of dysphagia demonstrated significantly worse swallow function as indicated by lower oropharyngeal swallow efficiency (OPSE), longer transit times, larger residues, and more swallows with aspiration.
  • The ability to accurately perceive swallowing function may be useful for self-monitoring changes in dysphagia status during a course of swallow therapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluoroscopy. Humans. Laryngeal Neoplasms / complications. Laryngeal Neoplasms / physiopathology. Male. Middle Aged. Mouth Neoplasms / complications. Mouth Neoplasms / physiopathology. Neoplasm Staging. Pharyngeal Neoplasms / complications. Pharyngeal Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Dysphagia.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc.
  • (PMID = 12112553.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA40007
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


16. Yoshida T, Tokashiki R, Ito H, Shimizu A, Nakamura K, Hiramatsu H, Tsukahara K, Shimizu S, Takata D, Okamoto I, Suzuki M: Therapeutic effects of a new photosensitizer for photodynamic therapy of early head and neck cancer in relation to tissue concentration. Auris Nasus Larynx; 2008 Dec;35(4):545-51
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic effects of a new photosensitizer for photodynamic therapy of early head and neck cancer in relation to tissue concentration.
  • OBJECTIVE: Talaporfin sodium (Laserphyrin, Meiji Seika, Tokyo, Japan) is a second-generation photosensitizer developed in Japan.
  • The objective of this study was to evaluate the efficacy and the pharmacokinetic characteristics in tumor tissues in patients with head and neck cancer. METHODS:.
  • (1) Four hours after administration intravenous injection of talaporfin sodium (40 mg/m(2)), 100mg tissue specimens were taken from the central part of the tumor.
  • Biopsies were performed at 4 weeks and at 3 months after treatment and periodically thereafter to confirm the treatment efficacy of photodynamic therapy (PDT).
  • RESULTS: Of the 14 patients who grope informed consent, more than 1 microg/g of talaporfin sodium was found in the tumor tissues in 13.
  • Moreover, in 9 patients, tumor-to-normal-tissue ratios ranged from 2.32:1 to 5.69:1, which indicates that more than double the amount of talaporfin sodium was maintained within the tumor than in normal tissues.
  • We have enrolled 22 patients with head and neck cancer with no clinically recognizable metastases after obtaining written informed consent to participate in this study.
  • CONCLUSIONS: The results using a combination of talaporfin sodium and PD laser achieved a primary treatment outcome equivalent to that of conventional PDT.
  • [MeSH-major] Laryngeal Neoplasms / drug therapy. Mouth Neoplasms / drug therapy. Pharyngeal Neoplasms / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Injections, Intravenous. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18242905.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; P4ROX5ELT2 / Talaporfin
  •  go-up   go-down


17. Biete Solà A, Marruecos Querol J, Calvo Manuel FA, Verger Fransoy E, Rovirosa Casino A, Grau de Castro JJ, de Las Heras González M, Ramos Aguerri A, Palacios Eito A, Veiras Candal C, Solano López MV: Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck. Clin Transl Oncol; 2007 Apr;9(4):244-50
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck.
  • INTRODUCTION: Standard fractionation radiation therapy (RT) combined with concomitant chemotherapy (CT) based on cisplatin schemes is actually the standard treatment for locally advanced non-resectable squamous cell carcinoma of head and neck (SCCHN).
  • The appearance of taxoids has introduced a new kind of treatment with high antitumoral power.
  • RESULTS: The mean total delivered dose of RT was 70'2 Gy (range 64-74 Gy).
  • The median and mean duration of time were 63 days and 61 days (range 49-103 days) respectively.
  • After a median time control of 19 months (range 3.3-42.2 months), the response rate was 83.4%.
  • The median time to local progression was 16.4 months (95% confidence interval [CI]=4.4-28.4 months).
  • The median survival time was 26.9 months, with one- and two-year overall survival of 66.9% (95% CI=48.1-85.7%) and 57.5% (95% CI=37.3-77.7%) respectively.
  • The median duration time response was 15.1 months (95% CI=3.7-26.5 months).
  • The median time until treatment failure was 9.4 months (95% CI=4.7-14.1).
  • CONCLUSIONS: Although therapeutics results are equivalent to cisplatin schemes of concurrent CT-RT, mucositis and cutaneous toxicity registered in this trial must be considered as limiting factors to application of this new approach.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Confidence Intervals. Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / radiotherapy. Larynx / pathology. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Neoplasms, Multiple Primary / radiotherapy. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / mortality. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / radiotherapy. Pharynx / pathology. Radiotherapy / adverse effects. Radiotherapy Dosage. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462977.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


18. Courtois A, Foehrenbach H, Maszelin P, De Dreuille O, Garcia D, Kossowski M, Merlet P, Gaillard JF, Poncet JL: [Positron emission tomography in head and neck oncology: five cases]. Ann Otolaryngol Chir Cervicofac; 2001 Sep;118(4):254-60
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Positron emission tomography in head and neck oncology: five cases].
  • FDG-PET (18-fluoro-desoxyglucose positron emission tomography) is a fonctionnal imaging method based on the high rate of glycolysis in different types of cancer-cells.
  • For primary assessment of cervicofacial carcinomas, different imaging techniques such as CT and MRI have improved tumor staging.
  • This diagnostic tool consequently is greatly helpful for detection and post-therapeutic evaluation of head and neck carcinomas and their recurrence.
  • 18-FDG-PET is currently under evaluation as a tool for detecting cervical lymph nodes and early assessment of response to chemotherapy.
  • [MeSH-major] Head and Neck Neoplasms / radionuclide imaging. Tomography, Emission-Computed
  • [MeSH-minor] Fluorodeoxyglucose F18. Humans. Laryngeal Neoplasms / radionuclide imaging. Lymphatic Metastasis / radionuclide imaging. Male. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasms, Unknown Primary / radionuclide imaging. Pharyngeal Neoplasms / radionuclide imaging. Prognosis. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11679846.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


19. Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC: Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. Radiother Oncol; 2009 Jul;92(1):100-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients.
  • Tumor stage was IVA in 9%, IVB in 51%, and IVC in 40%.
  • Before 1988 adjuvant treatment consisted of conventional radiotherapy (RT) and/or chemotherapy (CT).
  • This consists of locoregional RT in 46 fractions of 1.1 Gy, given twice daily, followed by prophylactic irradiation of the lungs (PLI) in 5 daily fractions of 1.5 Gy.
  • Acute toxicity in the protocol group was significantly higher than in the nonprotocol group, with 46% versus 11% grade 3 pharyngeal and/or esophageal toxicity.
  • CONCLUSION: Despite the ultimately dismal prognosis of ATC-patients, multimodality treatment significantly improved local control and improved the median survival.
  • [MeSH-major] Carcinoma / therapy. Neoplasm Recurrence, Local. Thyroid Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328572.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


20. Gurney TA, Eisele DW, Orloff LA, Wang SJ: Predictors of quality of life after treatment for oral cavity and oropharyngeal carcinoma. Otolaryngol Head Neck Surg; 2008 Aug;139(2):262-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of quality of life after treatment for oral cavity and oropharyngeal carcinoma.
  • BACKGROUND: Treatment for head and neck cancer, including surgery, radiation, and chemotherapy, can impact quality of life.
  • Eighteen percent had free-tissue transfer (fibula free flap in 8% and radial forearm free flap in 10%).
  • CONCLUSION: Stage, gastrostomy-tube dependence, complication, recurrence, and treatment modality influence quality of life.
  • A better understanding of the impact of oral cavity and oropharyngeal cancer treatment on quality of life will enable us to better advise our patients.
  • [MeSH-major] Mouth Neoplasms / therapy. Pharyngeal Neoplasms / therapy. Quality of Life
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Predictive Value of Tests. Regression Analysis. Surgical Flaps. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656726.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Morton RP, Thomson VC, Macann A, Gerard CM, Izzard M, Hay KD: Home-based humidification for mucositis in patients undergoing radical radiotherapy: preliminary report. J Otolaryngol Head Neck Surg; 2008 Apr;37(2):203-7
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were no demographic differences between the study and control groups, but the study group had significantly more advanced cancer (stage IV; p = .0307) and significantly higher total fractions and days treated (p < .01).
  • CONCLUSION: Humidification of inspired gas offers a simple, drug-free option for managing a number of the adverse mucosal effects of radiation and chemoradiation in head and neck cancer patients.
  • [MeSH-major] Home Nursing. Humidity. Mouth Neoplasms / radiotherapy. Nebulizers and Vaporizers. Pharyngeal Neoplasms / radiotherapy. Radiation Injuries / therapy. Stomatitis / therapy
  • [MeSH-minor] Case-Control Studies. Combined Modality Therapy. Dose Fractionation. Follow-Up Studies. Humans. Neoplasm Staging. Patient Admission / statistics & numerical data. Patient Compliance / statistics & numerical data. Patient Satisfaction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19128613.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


22. Lu X, Hu C, Ji Q, Shen C, Feng Y: Squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: the impact of radiotherapy. Tumori; 2009 Mar-Apr;95(2):185-90
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS AND BACKGROUND: Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site constitute about 5% of the total head and neck cancer, cases.
  • The management of these patients is still a therapeutic challenge.
  • Radiotherapy was delivered to the bilateral neck and pharyngeal mucosa (extensive field) in 11 patients (18.3%), to the bilateral neck in 24 patients (40.0%), and to the ipsilateral neck in 25 patients (41.7%).
  • Fourteen patients (23.3%) also received chemotherapy.
  • The primary tumor emerged in 23.3% of patients treated with ipsilateral and bilateral neck irradiation and in 12.5% of patients irradiated by extensive field (P = 0.469).
  • Extensive irradiation results in a lower trend of emergence of the primary tumor than when patients are treated with ipsilateral and bilateral irradiation, but there is no significant difference in overall survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neck. Neck Dissection. Neoplasm Staging. Prognosis. Radiotherapy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579864.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Nasr Ben Ammar C, Kochbati L, Lejri N, Chaouache K, Frikha H, Besbes M, Touati S, Ben Abdallah M, Maalej M: [Prognostic value of parapharyngeal extension in nasopharyngeal carcinoma]. Tunis Med; 2009 Dec;87(12):814-7
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: This study evaluated the prognostic value of the Para pharyngeal space involvement in nasopharyngeal carcinoma T 2 disease (UICC 1997 classification).
  • METHODS: From January 1997 and December2001; 32 patients with nasopharyngeal carcinoma were examined by CT scan and according to the 1997 International Union Against Cancer (UICC) staging system, 15 had stage T2a M0 (G1) and 17 T2bM0(G2).
  • Both neoadjuvant chemotherapy and radiotherapy were performed for advanced N disease and only radiotherapy for NO.
  • The completely clinical remission after chemotherapy was 12.5% (G1) and 53% (G2), partial remission was 25% (G1) and 35% (G2).
  • CONCLUSION: Parapharyngeal tumor involvement affects local and regional tumor failure.
  • Subclassification of T2 disease into T2a/T2b should have an impact on treatment strategies.
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20209847.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down






Advertisement